1,720,959 research outputs found
Hyperlipidemia in a myeloma patient after bortezomib treatment
No full textWe read with great interest the article by Gotoh et al. [1], inwhich they reported about a multiple myeloma patient refractory to VAD therapy who developed hyperlipidemia (total cholesterol, TC, 388 mg/dl and triglycerides, TG, 411 mg/dl) and multiple lipoma after two courses of Bortezomib, dexamethasone. We would like to share some experience and raise few questions about it
Lenalidomide on alternative days is effective in myelodysplastic syndrome with 5q- deletion
No full textLenalidomide is the treatment of choice in low-risk patients with myelodysplastic syndrome (MDS) and 5q- deletion, at the standard dose of 10 mg for 21 d of every 28-d cycle (Giagounidis et al, 2008). The main response criteria is to achieve blood transfusion independence and recent data reported a response rate of more than 60% in this subset of patients (Ja ̈dersten & Hellstro ̈m-Linderberg, 2009). Nevertheless
this effective treatment frequently induce severe (World Health Organization grade III–IV) neutropenia (55% of treated patients) and thrombocytopenia (44% of patients) at least during the initial 2–3 months. Another problem to be considered is the high cost of this standard therapy, as recently highlighted (Stone, 2009). One way to reduce toxicity has been reported by lowering the standard dose from 10 to 5 mg/d for 21 d (Giagounidis et al, 2008), but this schedule did not substantially affect the cost, because of the tablets’ unit price. On this particular issue we would like to report our pivotal experience in six patients treated with lenalidomide at 10 mg on alternative days for 21 d every 28 d. Our intent was to maintain the same efficacy, reduce treatment-related toxicity and also lower the cost of treatment. Moreover, there are no published data to date about the target plasma concentration of lenalidomide required to effectively inhibit the del 5q clone
Safety and efficacy of bortezomib, melphalan and low doses dexamethasone (VM-dex) in newly diagnosed patients with multiple myeloma
No full textVery late relapse in a patient with chronic myeloid leukemia in sustained complete cytogenetic response under imatinib
No full textLow-dose oral fludarabine plus cyclophosphamide as first-line treatment in elderly patients with indolent non-Hodgkin lymphoma
No full textTwenty-five elderly patients with untreated indolent non-Hodgkin lymphoma were treated with oral fludarabine 25 mg/m2/d (40 mg total dose) and cyclophosphamide 150 mg/m2/d, both for four consecutive days, repeated every 28 d for four cycles. In all, 21 (84%) patients were responsive: 10 patients achieved complete remission while partial response was obtained in 11. During an observation period of 37 months, there was an overall survival rate of 70% and a median event-free survival of 20 months. Haematological and extra-haematological toxicity were mild. This reduced-dose Flu-based oral regimen showed good efficacy and was simple to administer on an outpatient basis. © 2007 The Authors
Going Beyond Counting First Authors in Author Co-citation Analysis
Full text linkThe present study examines one of the fundamental aspects of author co-citation analysis (ACA) - the way co-citation
counts are defined. Co-citation counting provides the data on which all subsequent statistical analyses and mappings
are based, and we compare ACA results based on two different types of co-citation counting - the traditional type that
only counts the first one among a cited work's authors on the one hand and a non-traditional type that takes into
account the first 5 authors of a cited work on the other hand. Results indicate that the picture produced through this non-traditional author co-citation counting contains more coherent author groups and is therefore considerably clearer. However, this picture represents fewer specialties in the research field being studied than that produced through the traditional first-author co-citation counting when the same number of top-ranked authors is selected and analyzed. Reasons for these effects are discussed
Quantitative CT perfusion measurements in Hodgkin lymphoma a comparison with 18-Fluorodeoxyglucose positron emission tomography (FDG-PET): preliminary experience.
No full textVariations on the Author
Full text link“Variations on the Author” discusses two of Eduardo Coutinho’s recent films (Um Dia na Vida, from 2010, and Últimas Conversas, posthumously released in 2015) and their contribution to the general question of documentary authorship. The director’s filmography is characterized by a consistent yet self-effacing form of authorial self-inscription: Coutinho often features as an interviewer that rather than express opinions propels discourses; an interviewer that is good at listening. This mode of self-inscription characterizes him as an author who is not expressive but who is nonetheless markedly present on the screen. In Um Dia na Vida, however, Coutinho is completely absent form the image, while Últimas Conversas, on the contrary, includes a confessional prologue that moves the director from the margins to the center of his films. This article examines the ways in which these works stand out in the filmography of a director who offers new insights into the notion of cinematic authorship
Quantitative CT perfusion measurements during and after therapy in Hodgkin lymphoma: comparison with FDG-PET - Initial experience
No full text- …
